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Background: Increased detection of tuberculosis (TB) using intensified or active case finding (ICF) is one of the
cornerstones of the Stop TB Strategy, and contrasts with passive case finding (PCF) which relies on self-reported
symptoms. There is no clear guidance on implementation strategies. We implemented ICF in addition to ongoing
PCF in our large urban HIV clinic in July 2010 using a twice-daily announcement screen method by a trained peer
educator, asking waiting patients to self-refer to a trained peer supporter for screening of TB symptoms. We sought
to determine the associated effect on TB case detection.
Methods: Suspects were investigated by sputum smear, chest X-ray and ultrasound, if indicated. Routinely
collected clinical and laboratory data were merged with the ICF register and TB clinic data for patients attending
the clinic in 2010. We compared the yield of TB cases (defined as the prevalence of newly diagnosed TB cases in
the screened population), the type of TB diagnosed and the total cost per TB case identified (in United States
Dollars [USD]) for the period before and after ICF implementation.
Results: Of the 20,456 patients who visited the clinic in 2010, 614 were identified as TB suspects, 220 pre-ICF and
394 post-ICF (229 via PCF and 165 via ICF). The proportion diagnosed with TB dropped from 66% to 48% (60% in
suspects identified through PCF and 31% through ICF). During the post-ICF period, TB suspects identified through
ICF compared to PCF identification were more likely to be female, older, on ART and to have been enrolled in HIV
care for a longer duration. The yield of combined PCF and ICF screening was 1.4% pre-ICF and 1.7% post-ICF with a
cost per TB case identified of 12.29 USD and 21.80 USD, respectively.
Conclusions: Implementation of ICF in a large HIV clinic yielded more TB suspects and cases, but substantially
increased costs and was unable to capture the majority of TB suspects who were referred for diagnosis by clinicians
through PCF. The overall yield of TB cases in a mature HIV clinic was low, although targeted screening of those
recently enrolled in care may increase the yield.
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HIV is the most important risk factor for the develop-
ment of tuberculosis (TB). People living with HIV are
21-34 times more likely to develop TB than the HIV-
uninfected [1]. TB is a leading cause of death among
HIV infected people with 22% of all deaths attributable
to TB.
In 2004, collaborative activities to reduce the burden
of TB-HIV co-infection were added to the Stop TB
Strategy of the World Health Organization (WHO) [2].
These activities include provision of antiretroviral ther-
apy (ART) and the “3Is”: intensified case finding (ICF),
isoniazid preventive therapy (IPT) and infection control.
ICF refers to regular screening of all people with or at
high risk of HIV or, in congregate settings, for symptoms
of TB disease followed by prompt diagnosis and treat-
ment [3]. It is the “gatekeeper” of the “3Is” as it identifies
eligible patients for IPT and aids infection control [3,4].
It differs from passive case finding (PCF) which detects
TB cases among symptomatic patients presenting for
diagnosis and treatment of symptoms [5].
Uganda is one of the 22 WHO TB high-burden coun-
tries with an HIV prevalence of 6% [1,6]. The case detec-
tion rate of 61% in 2010 falls short of the WHO target
of 70%. In order to increase the number of HIV-positive
patients diagnosed with TB, the Ugandan Ministry of
Health (MoH) in October 2008 issued a mandate for all
health clinics to start ICF. In collaboration with the Na-
tional Tuberculosis and Leprosy Programmed (NTLP), it
developed a screening form to be administered in all
health care settings to aid in the detection of tubercu-
losis among high-risk groups (people living with HIV/
AIDS, or contacts of known TB patients).
Three ways to implement ICF in our high-burden HIV
clinic in Kampala were tested for feasibility in October
2009; (1) the individual screen method: every patient
was screened upon entry to the waiting area; (2) the pos-
ter screen method: posters in English and Luganda (the
most widely spoken local language) were placed in the
waiting area and included educational bullet points
about TB and TB-HIV co-infection, the ICF screening
questions, and instructions to approach a designated
peer supporter (an IDI patient who receives a reimburse-
ment for provided services in the clinic) if a patient
recognized any of these symptoms; and (3) the an-
nouncement screen method: a trained peer educator
gave twice daily presentations in English and Luganda
on TB and TB-HIV co-infection and the ICF screening
questions in the waiting area, asking waiting patients to
approach a trained peer supporter for screening if they
harbored any of the symptoms. Each method was piloted
on 2 clinic days and then compared. The first method
necessitated 4 additional full-time screening staff who
only managed to screen 78% of patients. Furthermore,the increased TB suspect workload was unsustainable
due to the additional human resource requirements, al-
though arguably the workload could decrease over time.
The second method was not feasible as 23% of patients
reported being illiterate. The third method identified a
similar number of TB cases as the first method with less
increase in workload. Therefore, we decided to imple-
ment ICF using the announcement screen method. In
this study we set out to determine the associated effect
on case detection of TB.
Methods
Setting
The Adult Infectious Diseases Clinic at the Infectious
Diseases Institute (IDI) is a large urban HIV clinic in
Kampala, Uganda, which provides outpatient HIV care
to approximately 10,000 active patients. Around 600 pa-
tient visits are scheduled daily; the majority of these
(85%) are scheduled monthly return visits for chronic
HIV care and medication refills. The other 15% are un-
scheduled emergency visits, new patient visits or refer-
rals. The HIV and TB-HIV outpatient clinics at IDI have
been described in detail previously [7,8]. In brief, care is
based on the Uganda national guidelines, recommending
co-trimoxazole prophylaxis for all HIV-infected persons
and, at the time of our study, provision of ART to all
with a CD4+ T cell (CD4) count lower than 250 cells/
mm3 [9]. In 2008, an outdoor integrated TB-HIV clinic
was set up to standardize the clinical management of
patients suspected of or with TB-HIV co-infection [8]. It
serves around 25 to 45 patients daily and is staffed by
dedicated doctors and nurses trained in TB and HIV co-
management. The TB-HIV clinic provides all care for
both TB and HIV (including provision of ART, diagnosis
and treatment of any other opportunistic infections).
Before the introduction of ICF, patients suspected of
having TB were identified via PCF and sent to the TB-
HIV clinic by the triage nurses in the general HIV out-
patient clinic or by the doctors from their consultation
rooms. All TB suspects were seen in the TB-HIV clinic
for diagnosis and treatment. TB investigations including
sputum smear microscopy, chest radiology, abdominal
ultrasonography, lymph node biopsy and fine needle as-
piration for microscopy were used. Mycobacterial cul-
tures were not routinely available due to cost. Diagnosis
was based on these investigations and occasionally on
clinical presentation only. TB was treated according to
the National TB and Leprosy Program (NTLP) guide-
lines [10].
Implementation of ICF
The MoH ICF screening form consisted of a set of five
TB screening questions: cough (for more than 2 weeks),
hemoptysis, fevers (for more than 3 weeks), excessive
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(more than 3 kilograms in one month). A person with
any of these symptoms was considered a TB suspect and
should be investigated for TB. This form was to be used
for TB screening in HIV care settings at each clinic visit
and was to be administered by trained personnel, either
a health care professional or lay person, at the health fa-
cility. Per the MoH recommendations, all patients visit-
ing the HIV clinic were targets of ICF screening.
In July 2010, we implemented ICF clinic-wide using
the announcement screen method. Two trained peer
supporters were designated and trained to give twice
daily presentations on TB and TB-HIV co-infection and
the ICF screening questions (in English and Luganda) in
the general clinic waiting area, asking waiting patients to
approach one of them if they had any of the described
symptoms. They were also to screen the patients pre-
senting themselves to them afterwards and to record all
who reported one or more of the symptoms on the
screening form in a register. They referred these TB sus-
pects to the outdoor TB-HIV clinic directly, where they
were further investigated for TB according to the clinic
guidelines. Their scheduled HIV clinic visit was also
completed in the TB-HIV clinic. In addition to ICF, TB
suspects continued to be identified by PCF during their
encounter with the HIV clinic staff at their scheduled
visit.
Study design, selection criteria and definitions
This study used a retrospective cohort study design in
which we compared two periods: six months before ICF,
January to June 2010 (pre-ICF), and 6 months after ICF im-











Figure 1 Study overview: screening for TB before and after implemen
finding; TB, tuberculosis.All patients with an IDI clinic visit during 2010 were eli-
gible for inclusion in our analysis. Only one clinic visit per
patient per study period was used to calculate the screened
population. The median number of repeat visits per patient
per period was also determined. A TB suspect was defined
as a patient who was referred to the TB clinic for TB inves-
tigation, irrespective of their method of identification (PCF
or ICF). Identification via PCF or ICF in the post-ICF
period was determined by the ICF register in which all sus-
pects identified via ICF were recorded (see above). A TB
diagnosis was defined as having received a TB diagnosis
from the TB-HIV clinic medical officer, based on the proce-
dures explained above. TB treatment was defined as having
been started on TB treatment.
All patients who screened positive for TB by the peer
supporter, but who did not classify as TB suspects on ar-
rival at the TB clinic (n = 50), who never presented to
the TB clinic for further work-up of TB (n = 32), or for
whom no TB work-up data was available and whose files
were unavailable for review (n = 56) were excluded. We
also excluded patients transferred from other health cen-
ters with an existing TB diagnosis and patients who were
already on TB treatment.Study outcomes
The primary outcome measure was the yield of newly
diagnosed TB patients identified (defined as the preva-
lence of newly diagnosed TB cases in the screened popu-
lation). Secondary outcomes included the type of TB
diagnosed and the total cost per TB case identified. All
outcomes were compared for the period before and after
ICF implementation.TB suspects 
 cases TB cases 
suspects 




Screen by peers 
Post-ICF period 
 PCF                                                  ICF 
tation of ICF. Note: ICF, intensified case finding; PCF, passive case
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Routinely collected data on clinical parameters, ART and
adherence, WHO stage, toxicities and opportunistic
infections of all IDI patients were entered into a data-
base, to which laboratory data were added electronically.
We extracted data from this database, from the ICF
register (of all patients who screened positive by the
trained ICF peer supporters), the electronic TB-HIV
clinic database (which contained routinely collected data
on TB symptoms, diagnosis, treatment and follow-up at
each TB clinic visit), and the NTLP TB register (of all
patients on TB treatment at IDI). We merged these data
to arrive at a complete dataset of all patients who had
visited IDI in 2010, and which included detailed infor-
mation on those screened for TB. We performed chart
reviews to validate any inconsistent data between these
data sets. Patients lost to follow-up were recorded at
each stage of the diagnostic process from screening to
treatment. This study was performed as part of regular
clinic monitoring and evaluation for continuous quality
improvement that was approved by the Institutional Re-
view Boards of IDI, Makerere University College of
Health Sciences and the Uganda National Council for
Science and Technology.
Data analysis
The absolute numbers and proportions of suspects,
patients having undergone TB investigations, patients
with a final diagnosis (TB yes/no) and patients treated
for TB in both periods were compared. Comparisons
were done by period, by method of identification and by
time since registration at the IDI (classified as enrolment
into care in the 3 months prior to their becoming a TB
suspect or after). Baseline characteristics were compared
using Chi-squared, two-tailed student t-tests and, where
appropriate, two-sample Wilcoxon rank-sum tests.
Ninety-five percent confidence intervals (CI) were used
and P-values ≤0.05 were considered to be statistically
significant. Analyses were conducted using STATA ver-
sion SE 11.1 (College Station, Texas, USA).
Cost inputs and analysis
We assessed all costs to perform the screening and diag-
nosis of TB suspects, including the costs for investiga-
tions and for the peer supporters performing the
screening. The peer supporters had no other clinic re-
sponsibilities than the TB screening programmed. Costs
were the actual price paid for these services in 2010. As
the real number of investigations performed was not
captured in our database, we estimated these based on
current clinic standard operating procedures and on the
proportion of extrapulmonary TB diagnosed in the pre-
ICF and post-ICF periods (subdivided by suspects identi-
fied via PCF and via ICF). We assumed that all TBsuspects underwent a chest X-ray and sputum smear
analysis (2 smears). We assumed that half of the investi-
gations for extrapulmonary TB consisted of a lymph
node aspirate and the other half of an abdominal ultra-
sound. Other investigations such as a lymph node biopsy
and pleural fluid analysis were performed very infre-
quently, and were therefore not included in the analysis.
As the TB clinic and staff remained the same in the pre-
and post-ICF periods, these costs were not included, as
were costs for routine HIV care, such as laboratory
investigations. All costs were totaled and divided by the




A total of 9,931 patients visited the IDI in the six
months pre-ICF and 10,525 in the six months post-ICF
implementation. These patients visited the clinic a mean
of 4.7 times (standard deviation [SD], 1.9) per person in
the pre-ICF period and 4.8 (SD, 2.0) times in the post-
ICF period. More women than men visited the clinic
(68% in both periods), and 74% and 72% were on ART at
their first visit during the pre- or post-ICF period, re-
spectively. In the pre-ICF period, patients had been
registered at the IDI for a median of 1441 (interquartile
range [IQR], 563, 1769) days before their first clinic visit
during those six months; in the post-ICF period this was
a median of 1536 (IQR 511, 1930) days.
A total of 614 patients were suspected of having TB
over both periods studied: 220 (2.2%) pre-ICF and 394
(3.7%) post-ICF, of which in the latter 165 (41.9%) were
identified via ICF and 229 (58.1%) via PCF. Overall, 356
(58%) were women and 217 (35%) were on ART. See
Table 1 for the baseline characteristics of all three
groups. Suspects identified via PCF in both periods
seemed to be relatively similar, but suspects identified
through ICF as opposed to through PCF during the
post-ICF period were more likely to be female, older, on
ART and to have been registered at the IDI for a longer
duration.
Outcomes before and after ICF
Absolute numbers of suspects, suspects investigated for
TB, diagnosed with and treated for TB all increased after
ICF implementation (Figure 2). The number of suspects
almost doubled from 220 to 394. The proportion of sus-
pects investigated for TB remained high at 96% in the
pre-ICF period and 95% in the post-ICF period. Of
those, the proportion diagnosed with TB dropped from
66% in the pre-PCF to 48% in the post-ICF period. In
the post-ICF period, 49 out of 158 (31%) of investigated
ICF suspects and 131 out of 217 (60%) investigated PCF
suspects were diagnosed with TB.
Table 1 Patient characteristics
Pre-ICF Post-ICF Post-ICF P-value P-value




N= 220 (100%) N=229 (58%) N=165 (42%)
Sex (n [%]) Male 112 (51) 95 (41) 51 (31) 0.045 0.032
Female 108 (49) 134 (59) 114 (69)
Age (years, mean [SD]) 35 (9.2) 36 (10.1) 40 (10.0) 0.300 <0.001
ART (n [%])* Yes 68 (31) 75 (33) 74 (45) 0.411 0.007
No 149 (68) 147 (64) 91 (55)
Time at IDI since registration (days, median [IQR]) 94 (4, 1005) 57 (1, 1437) 1015 (128, 1830) 0.696 <0.001
Symptoms (n [%])* Pulmonary 164 (75) 187 (82) 138 (84) 0.033 0.011
Only B-symptoms 20 (9) 23 (10) 5 (3)
Missing 36 (16) 19 (8) 22 (13)
TB patients TB patients TB patients
N= 139 (63%) N=131 (57%) N=49 (30%)
Type of TB (n [%]) Smear positive 60 (43) 39 (30) 19 (39) 0.051 0.824
Smear negative 20 (14) 28 (21) 12 (24)
Extrapulmonary 54 (39) 51 (39) 15 (31)
Missing 5 (4) 13 (10) 3 (6)
*Data on ART use was not available for 10 patients (3 pre-ICF and 7 post-ICF of which all PCF).
Note: ART, antiretroviral therapy; ICF, Intensified Case Finding; IDI, Infectious Diseases Institute; IQR, interquartile range; PCF, passive case finding; SD, standard
deviation; B-symptoms: fevers or night sweats for more than 3 weeks and/or weight loss (>3 kilograms in one month); vs, versus.
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prior to their becoming a TB suspect (n = 261 or 43% of
all suspects) were more likely to be diagnosed with TB
than those who had been at the IDI for more than
3 months (63% versus 44%, P < 0.001). Post-ICF, these
newly enrolled suspects primarily presented via PCF
(118 out of 152 [78%]) and less via ICF (34 out of 152
[22%]). There was no difference in the type of TB diag-
nosed between the suspects identified in the pre- and
post-ICF period, or between the methods of their identi-
fication (Table 1).Yield of ICF
The yield of screening was 1.4% (139 of 9931) in the pre-
ICF period (only PCF) and 1.7% (180 out of 10525) in the
post-ICF period (ICF and PCF combined), or a prevalence
of 1,400/100,000 and 1,700/100,000, respectively.Costs
By adding up all costs involved with the screening and
the diagnosis of TB suspects before and after ICF imple-
mentation and then dividing this amount by the num-
bers of TB cases, we found that the cost per TB case
found almost doubled from 12.29 USD pre-ICF to 21.80
USD post-ICF (Table 2). The greatest cost difference was
incurred by the increase in numbers of investigations
(sputum smears and chest X-rays) and the additionalcost of the screening staff. Costs increased by 130% and
TB cases identified by 30%.
Discussion
We found that implementation of ICF by the announce-
ment screen method in a large HIV clinic led to a 76%
increase in the number of TB suspects identified, with
only a 30% increase in newly diagnosed TB cases. PCF
during the post-ICF period continued to identify a simi-
lar number of TB suspects compared with the pre-ICF
period, even though ICF was performed at an earlier
stage of the clinic visit than PCF. Different subsets of
patients were identified through the two parallel screen-
ing methods.
The reported yield of new TB cases identified by ICF
varies greatly, depending on the HIV prevalence in the
population at risk studied, the country-specific TB
prevalence and the method of screening used (symptom-
based or not). According to a recent meta-analysis of
studies of ICF in HIV-infected people in resource-
limited settings, it ranged from 2.2% in contact-tracing
exercises to 8.2% in medical and antiretroviral clinics
[11]. Factors associated with a higher yield of ICF
included the screening of all patients regardless of symp-
toms, and ICF in countries with higher TB prevalence.
Screening strategies also vary widely and usually involve
a set of questions. Absence of current cough, night
sweats, weight loss and fever was associated with a low
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Pre-ICF period Post-ICF period
Figure 2 Patient flow before and after ICF Implementation. This figure shows the flow of patients in the two periods assessed in this study.
1Pre-ICF, 9 were not investigated (4%): 3 LFU, 1 died, 5 charts missing. Post-ICF, 14 were not investigated (3 LFU, 1 psychotic, 1 LFU to general
clinic, 9 missing) and 5 charts were missing. 2Pre-ICF, in 66 no TB was found (31%); 6 diagnoses were missing (3 LFU, 1 died, 2 charts missing).
Post-ICF, no TB was found in 185 (49%); 10 diagnoses were missing (4 LFU, 2 died, 1 LFU to general clinic, 3 charts missing). 3Pre-ICF, 8 were not
treated for TB (1 LFU, 2 died, 5 missing). Post-ICF, 15 (8%) were not treated for TB (2 LFU, 5 died, 8 charts missing). Note: ICF, intensified case
finding; LFU, loss to follow-up; TB, tuberculosis.
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dependent on the prevalence of TB in the screened
population with the negative predictive value decreasing
from 99.7% to 92.3% with an increase in TB prevalence
from 1% to 20%.
The yield of our symptom-based screening method
was lower: at 1.4% and 1.7% of the active attending pa-
tient population in the pre-ICF and post-ICF period, re-
spectively. In Uganda, prevalence estimates of newly
diagnosed TB identified by symptom-based ICF screen-
ing programmes vary between 7.2% in a rural cohort ofTable 2 Costs incurred in the pre- and post-ICF periods
Item Unit cost (UGX)1 U
Sputum smear (100%)2 10,000
Chest X-ray (100%) 5,000
Ultrasound (20%) 10,0003
Lymph node aspirate (20%) 5,000
Peer supporter 80,000 per week x 25 weeks
Total costs
Cost per TB case
1Based on exchange rate 1000 UGX= 0.43156 USD (1/7/2010).
2Consisting of 2 sputum samples per TB suspect.
3Of which patients contribute 50% out of their own pocket.
Note: ICF, Intensified Case Finding; NA, not applicable; PCF, passive case finding; TB,ART initiators, 3.6% in a rural cohort of patients
screened for ART eligibility and 1.4% among new
patients enrolling in an HIV clinic in the same hospital
complex [13-15]. Our study population represents the
population of a “mature” HIV clinic, with the majority of
patients on ART and therefore less likely to have
unrecognized TB. Also, regular TB screening via PCF
may have already reduced the burden of infectious
patients and thus the nosocomial transmission of TB,
leading to a reduced TB incidence in our patient popula-





34.52 per week NA 863.11
1708.96 3923.71
12.29 21.80
tuberculosis; USD, United States Dollars.
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missing of TB suspects (possibly also due to stigma, evi-
denced by the large proportion of TB suspects identified
by PCF after ICF had been implemented), or a sub-
standard laboratory performance, although regular ex-
ternal quality control has not shown this to be the case.
The contribution of missed smear-negative, culture-
positive TB is unclear: we diagnosed smear-negative
pulmonary TB among 12% of coughing TB suspects in
both the pre- and post-ICF period, which was lower
than an estimated 19% smear-negative, culture-positive
TB diagnosed among IDI pulmonary TB suspects in an
earlier study (unpublished data from [16]). The effect of
routine use of TB culture or Xpert MTB/RIF in con-
firming these empirically treated TB cases should be
investigated, as well as the cost-effectiveness of such
strategies.
We attempted to implement ICF in a methodical and
feasible way using a method based on announcements.
The individual screening method would possibly have led
to identification of more suspects, but at a greater cost,
both monetary and human resource. We show that this
method is feasible, but less effective than PCF. The popu-
lation of TB suspects identified by this method of ICF was
different from the one identified through ongoing PCF in
the same period, as evidenced by their differing baseline
characteristics and the higher TB suspect to case ratio in
ICF versus PCF suspects. This could have been due to in-
adequate screening by the peer supporters, or to a higher
likelihood of more “experienced” patients presenting
themselves for screening. This correlates with our finding
that only one-fifth of TB suspects who were newly en-
rolled in HIV care were identified through ICF. Con-
versely, considering that the suspects identified through
PCF in both periods were relatively similar but differed
from those of the suspects identified through ICF, ICF
might have identified an additional subset of TB patients
which otherwise would have remained undiagnosed and
therefore infectious. Our results cannot confirm or ex-
clude this possibility, however. Additionally, stigma
attached to TB may result in the patient presenting to the
clinician when being asked the screening questions rather
than approaching the peer supporter in the waiting area.
Incomprehension of the message may also be a cause; ei-
ther due to a language barrier or because of the manner in
which the message is delivered. Our ICF method was very
dependent on how the person charged with giving the
announcements did this, and how he/she emphasized the
importance of knowing one’s “TB status”. The individual
screening method may arguably have fewer of these pro-
blems. Lastly, the announcements could possibly have
made PCF more effective, by sensitizing patients and mak-
ing them more likely to volunteer their symptoms during
their clinician visit.Costs per TB case identified rose from 12 to 22 USD
after implementation of ICF using the announcement
screen method. The increase was mainly due to the
higher suspect to case ratio and to the cost of the peer
supporters performing the screening. These were relative
costs, comparing costs pre- and post-ICF implementa-
tion. Absolute costs of screening programmes are highly
dependent on the work-up of TB suspects and compari-
sons across settings and countries are therefore difficult
to make. We lacked both cost and clinical inputs to do a
formal cost-effectiveness analysis. Our analysis was sim-
ple in nature and therefore did not take staff time or
treatment costs into account. The TB-HIV clinic staff in-
cluding the peer supporters would only have helped out
in the regular ART clinic on an ad-hoc basis. A formal
cost-effectiveness analysis is needed to inform practice
and should include the effect of ICF on TB transmission.
The cost-effectiveness of screening of the whole popula-
tion regardless of (the duration of ) symptoms, as pro-
posed by some [11,17], would have to be established.
This would not be feasible in our clinic without a com-
prehensive restructuring of the health care delivery at
IDI and without a significant increase in resources for
personnel and investigations.
Our findings raise the question how best to optimize
ICF in a setting like ours. As the majority of TB cases
were found among patients newly enrolled into HIV
care, it seems advisable to screen that part of the patient
population systematically, possibly using an individual
screening method. For patients in care for a longer
period of time, the optimal screening strategy is less ob-
vious. As clinicians are less likely to think of TB in stable
patients, there is a need for some form of additional
screening, especially if it would sensitize the patient to
report TB-symptoms during the formal encounter with
the HIV clinician. Targeted announcements such as in
our study might work for this category of patients. Opti-
mal screening frequencies should be established, for ex-
ample by comparing a strategy of screening at each
clinic visit with 3-monthly, 6-monthly or even yearly TB
screening.
Noteworthy was the high retention rate of TB sus-
pects: 95% and 96% underwent investigations. This was
substantially higher than in a similar screening pro-
grammed in Swaziland, where this was only 53% [18].
Limitations of our study were the retrospective study
design and the use of routinely collected data with miss-
ing data as a result. The 50 excluded patients who were
identified by ICF but did not qualify as a TB suspect on
arrival at the clinic, added to the increase in workload
after ICF implementation. Some of these were misidenti-
fied by the peer supporters, highlighting the need for
continuous retraining of lay health care workers. Others
purposefully reported TB symptoms at screening to
Hermans et al. BMC Public Health 2012, 12:674 Page 8 of 9
http://www.biomedcentral.com/1471-2458/12/674ensure being seen by a clinician in the TB-HIV clinic.
Interestingly, 32 patients were identified as TB suspects
by the peer supporter but were never seen in the TB
clinic, possibly due to long waiting times or to stigma
associated with TB. The potential TB suspects for whom
no data was available (n = 56) possibly belong to the
same category. Both point towards a possible systems
issue absorbing these patients in the TB-HIV clinic. Al-
though we tried to highlight differences in study popula-
tion, changes due to time-trends are a limitation of the
before-after study design. We feel that the limited period
of time in which the study was conducted was unlikely
to have a major impact on the results.
Sputum samples were investigated by light microscopy
using Ziehl-Neelsen staining in the pre-ICF period, while
an in-house LED-based fluorescence microscopy was
established at the start of the post-ICF period. However,
we do not believe the 10% sensitivity difference to have
influenced our case-detection in both periods greatly
[19]. We made assumptions of the numbers of investiga-
tions ordered for the costing analysis; however, as the
investigations did not differ hugely in price, we believe
that using the actual numbers would not change our es-
timate markedly. We also assumed a flat cost of 5,000
UGX (2.16 USD) for sputum smear microscopy, while
the in-house test implemented in the post-ICF period
was cheaper (true costs were not available). Our costing
analysis was therefore conservative.
Lastly, this method of ICF implementation would not
have been possible in a large clinic without resources for
the additional lay health care workers and investigations.
The IDI has more available tests for diagnosis and better
follow-up of the patients compared to most health care
settings in sub-Saharan Africa. Also, the on-site fluores-
cence microscopy services could handle the additional
sputum smears in a timely fashion. For ICF to be imple-
mented countrywide in Uganda and in other resource
limited settings, there would have to be a scale-up of
resources in order to train health care and lay workers
and to equip the laboratory systems to handle the extra
workload.
Conclusions
Implementation of ICF in a large, “mature” HIV clinic
using an announcement screen method yielded more TB
suspects and cases, but substantially increased costs and
was unable to capture the majority of TB suspects re-
ferred for diagnosis, potentially diluting an effect on in-
fection control. The overall yield of TB cases in a
mature HIV clinic was low, raising the question whether
ICF is cost-effective and affordable in such a setting. Re-
search into the optimization of ICF is needed, including
targeted screening strategies for those recently enrolled
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